Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The United Laboratories International Holdings ( (HK:3933) ) has issued an update.
The United Laboratories International Holdings has received U.S. FDA approval for an investigational new drug application for TUL108 for injection, a self-developed Class 1 novel broad-spectrum β-lactamase inhibitor intended for use in combination with meropenem to treat a range of serious infections, including complicated urinary tract, intra-abdominal, pulmonary and bloodstream infections. By targeting carbapenem-resistant Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii, the approval of TUL108’s IND is expected to reinforce the company’s leadership in the anti-infective segment and enhance its innovation profile and competitiveness, with anticipated long-term benefits for its overall market position and shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a pharmaceutical company focusing on anti-infective therapies, with research and development capabilities centered on novel drug discovery and injectable formulations. Through its wholly owned subsidiary Zhuhai United Laboratories Co., Ltd., the group develops innovative treatments targeting serious bacterial infections in key global markets.
Average Trading Volume: 9,721,894
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.28B
See more data about 3933 stock on TipRanks’ Stock Analysis page.